Olaparib (Lynparza) 50 mg capsules: Discontinuation

Astra Zeneca have discontinued the supply of olaparib (Lynparza) 50 mg capsules from 1 April 2021. 100 mg and 150 mg tablets remain available

Information for people taking Lynparza capsules

The supplier, Astra Zeneca, is no longer supplying Olaparib (Lynparza) 50 mg capsules. 

If you are currently using this product, you will need to talk to your health care professional about the best alternative for you. 

Using the tablets may be a suitable alternative. However, there are differences in the way the tablets and capsules work in your body. Your health care professional knows you and your clinical circumstances.

We know that changes to medication can be inconvenient. The decision to discontinue this product was made by the supplier.   

Information for prescribers

Do not start any new patients on olaparib 50 mg capsules. 

Support your patients who are currently taking olaparib 50 mg capsules to move to an alternative as soon as possible.  

The 100 mg and 150 mg olaparib (Lynparza) tablets remain available for supply and can be used as alternatives.

Please note, Lynparza tablets should not be substituted for Lynparza capsules on a milligram-to-milligram basis.

This is due to differences in the dosing and bioavailability of each formulation. The specific dosage recommendations for each formulation should be strictly followed.

Key dates

  • 1 April 2021 – Olaparib 50 mg capsule stock no longer available.
  • 1 July 2021 – Olaparib 50 mg capsule delisted from the Pharmaceutical Schedule. 

Who to contact

For further questions about the discontinuation of olaparib 50 mg capsules, contact Astra Zeneca:

If you have questions about funding for this or other products, email enquiry@pharmac.govt.nz